6,7-二(2'-甲氧基乙氧基)喹唑啉 | 1208902-93-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6,7-二(2'-甲氧基乙氧基)喹唑啉
• 英文名称: 6,7-di(2'-methoxyethoxy)quinazoline
• 英文别名: 6,7-bis(2-methoxyethoxy)quinazoline
• CAS: 1208902-93-5
• 化学式: C₁₄H₁₈N₂O₄
• 分子量: 278.308
• InChiKey: ZEIQULGRQBQNFX-UHFFFAOYSA-N

物化性质

• 沸点：
  418.8±45.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  62.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6,7-二(2'-甲氧基乙氧基)喹唑啉 在 过氧乙酸 、 硫酸 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以93%的产率得到6,7-二甲氧乙氧基喹唑啉-4-酮
  参考文献：
  名称：

  Facile and Efficient Oxidation of Quinazolines into Quinazolin-4(3H)-ones by Peracetic Acid

  摘要：

  A new approach to synthesize quinazoline-4(3H)-ones was achieved by oxidation of quinazolines using peracetic acid, which possesses some advantages of economic reagents, simplified operation, high efficiency, and environmental friendliness. Application of this method allowed us to synthesize a series of quinazolin-4(3H)-ones with different substituents at 6 and 7 positions in good to excellent yields, including the key intermediates of tyrosine kinase inhibitors such as PD153035, Erlotinib, and Gefitinib. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) for the following free supplemental resource(s): Full experimental and spectral details.]

  DOI：

  10.1080/00397911.2013.805230
• 作为产物：
  描述：

  埃罗替尼杂质 在 盐酸 、 铁粉 作用下， 以 乙醇 为溶剂， 生成 6,7-二(2'-甲氧基乙氧基)喹唑啉
  参考文献：
  名称：

  Facile and Efficient Oxidation of Quinazolines into Quinazolin-4(3H)-ones by Peracetic Acid

  摘要：

  A new approach to synthesize quinazoline-4(3H)-ones was achieved by oxidation of quinazolines using peracetic acid, which possesses some advantages of economic reagents, simplified operation, high efficiency, and environmental friendliness. Application of this method allowed us to synthesize a series of quinazolin-4(3H)-ones with different substituents at 6 and 7 positions in good to excellent yields, including the key intermediates of tyrosine kinase inhibitors such as PD153035, Erlotinib, and Gefitinib. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) for the following free supplemental resource(s): Full experimental and spectral details.]

  DOI：

  10.1080/00397911.2013.805230

文献信息

• POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF
  申请人：Li Jianqi

  公开号：US20110288086A1

  公开（公告）日：2011-11-24

  At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.

  至少选择一种活性药用成分来自公式V的多环喹唑啉，其药学上可接受的盐，以及药学上可接受的盐的水合物。所披露的活性药用成分可能是蛋白酪氨酸激酶抑制剂和/或极化激酶的抑制剂。这些活性药用成分可用于治疗对蛋白酪氨酸激酶抑制剂和/或极化激酶抑制剂治疗敏感的癌症。
• Antibodies directed to angiopoietin-2 and uses thereof
  申请人：AstraZeneca AB

  公开号：EP2284194A1

  公开（公告）日：2011-02-16

  Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

  描述了针对抗原 Ang-2 的抗体及其用途。特别是针对抗原 Ang-2 的全人源单克隆抗体。编码重链和轻链免疫球蛋白分子的核苷酸序列和氨基酸序列，特别是与跨越框架区和/或互补决定区（CDRs）的连续重链和轻链序列相对应的序列，特别是从FR1到FR4或CDR1到CDR3。表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其他细胞系。
• FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF
  申请人：Shenzhen Salubris Pharmaceuticals Co., Ltd.

  公开号：EP2592083A1

  公开（公告）日：2013-05-15

  Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

  本研究公开了融合喹唑啉衍生物及其作为蛋白酪氨酸激酶抑制剂和极光激酶抑制剂的用途。所述蛋白酪氨酸激酶抑制剂和极光激酶抑制剂可用于治疗癌症、白血病以及与分化和增殖有关的疾病。所述蛋白酪氨酸激酶和极光激酶双重抑制剂为下通式所代表的化合物或其盐类。
• A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines
  作者：Giovanni Marzaro、Adriano Guiotto、Giovanni Pastorini、Adriana Chilin

  DOI：10.1016/j.tet.2009.11.091

  日期：2010.1

  A novel strategy to prepare 4-anilinoquinazoline derivatives based on the oxidation of the quinazoline ring is described. Quinazoline oxidation has been investigated and improved, thus leading to an efficient and high yielding method to quinazolin-4(3H)-ones. Efficiency of this approach has been evaluated synthesizing four well known tyrosine kinase inhibitors and comparing the obtained yields with those achievable through conventional synthetic methods. (C) 2009 Elsevier Ltd. All rights reserved.
• QUINAZOLINE DERIVATIVES
  申请人：OSI Pharmaceuticals, LLC

  公开号：EP3103799B1

  公开（公告）日：2018-06-06